Elsevier

Vaccine

Volume 30, Issue 1, 9 December 2011, Pages 59-68
Vaccine

TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4+ memory T cell loss in SIVmac251-challenged rhesus macaques

https://doi.org/10.1016/j.vaccine.2011.10.043Get rights and content

Abstract

Adjuvant plays an important role in increasing and directing vaccine-induced immune responses. In a previous study, we found that a mucosal SIV vaccine using a combination of IL-15 and TLR agonists as adjuvant mediated partial protection against SIVmac251 rectal challenge, whereas neither IL-15 nor TLR agonists alone as an adjuvant impacted the plasma viral loads. In this study, dissociation of CD4+ T cell preservation with viral loads was observed in the animals vaccinated with adjuvants. Significantly higher levels of memory CD4+ T cell numbers were preserved after SIVmac251 infection in the colons of the animals vaccinated with vaccine containing any of these adjuvants compared to no adjuvant. When we measured the viral-specific CD8+ tetramer responses in the colon lamina propria, we found significantly higher levels of gag, tat, and pol epitope tetramer+ T cell responses in these animals compared to ones without adjuvant, even if some of the animals had similarly high viral loads. Furthermore, this CD4+ T preservation was positively correlated with increased levels of gag and Tat, but not pol tetramer+ T cell responses, and inversely correlated with beta-chemokine expression. The pre-challenged APOBEC3G expression level, which has previously been shown inversely associated with viral loads, was further found positively correlated with CD4+ T cell number preservation. Overall, these data highlight one unrecognized role of adjuvant in HIV vaccine development, and show that vaccines can produce a surprising discordance between CD4+ T cell levels and SIV viral load.

Introduction

Dramatic loss of resident memory CD4+ T cells in the intestine occurs within 2–3 weeks post-SIV-infection irrespective of the route of initial viral entry [1], [2], [3], [4], [5]. This rapid and profound depletion of CD4+ T cells is more severe in the gut mucosa than the other compartments [6], and hard to be reconstituted in patients even on highly active antiretroviral therapy (HAART) [2], [7]. Recently, a long-term benefit of protecting against gut mucosal [8], [9], and systemic CD4+ T cell loss [10] has been demonstrated. For example, long-term non-progressors (LTNPs) had a higher frequency of mucosal CD4+ T cells as compared to progressors [8], and early restoration of mucosal CD4+ memory CCR5+ T cells in the gut of SIV-infected rhesus predicted LTNP [9]. In a vaccine trial, Letvin et al. showed that preserved CD4+ central memory T cells several months after infection correlated with long-term protection and predicted the efficacy of an HIV-vaccine better than set-point viral load (VL) [10]. If CD4+ T cells were depleted during immunization as demonstrated by Vaccari et al., a decreased protection against SIVmac251 challenge was observed, which further confirmed the important role of CD4+ T cells in the course of HIV infection and AIDS development [11]. These studies suggested the significance of protecting mucosal/systemic CD4+ T cells from infection and destruction during HIV infection; however, current vaccine strategies hardly achieved this goal. Even if plasma and tissue viral loads were reduced in some of the macaque studies, significant mucosal CD4+ T cell preservation was not observed [17], [57]. Here we surprisingly observed the opposite discordance, namely that CD4+ T cells were preserved even when VL was not reduced. Although vaccine protection of CD4+ T cells may be expected to occur if VL is reduced, protection of CD4+ T cells without VL reduction is novel and unexpected, and requires further examination, as we have attempted here. Strategies that could protect against both systemic and gut mucosal CD4+ T cell loss during HIV/SIV infection would be desirable.

One way to achieve this, which we demonstrated in this study, was to use molecular adjuvants, such as Toll-like receptor (TLR) agonists and/or IL-15, during SIV vaccine immunization. It has been known that adjuvant plays an important role to increase the magnitude, breadth, and the quality of the immune responses, and vaccines with certain adjuvants confer better protection against the subsequent SIV/SHIV challenge. TLR agonists activate and mature dendritic cells to enhance immune responses [12], [13], [14], [15], [16], while IL-15 promotes the homeostatic expansion of CD8+ memory T cells [17], [18], [19], [20], and the induction of higher avidity, longer-lived T cells [21], [22], [23], [24]. Both have been shown to be good adjuvants in mouse and macaque models [12], [13], [15], [16], [23], [24]. In our current macaque study, we found that the combination of TLR agonists and IL-15 as an adjuvant in a mucosal SIV vaccine regimen enhanced the quality of vaccine-induced responses, which included long-lived APOBEC3G (A3G) and polyfunctional CD8+ T cell responses, and partially protected the SIVmac251-challenged macaques [25]. Though we did not observe any reduction of VLs in the animals vaccinated with the same mucosal SIV vaccine regimen with only TLR agonists or IL-15 alone as an adjuvant [25], we have now surprisingly found a significant preservation of CD4+ T cell numbers in the colon mucosa (and to a lesser extent in the ileum and peripheral blood) of these animals 6 months post-infection.

In an attempt to explore the possible mechanisms of this CD4+ T cell preservation in the SIVmac251 infected macaques, we first examined whether the pre-challenge A3G expression levels and antigen-specific polyfunctional CD8+ T cell responses, which we have explored in our previous study, were correlated with CD4+ T cell preservation. Interestingly, A3G, which was previously found inversely correlated with plasma VL reduction, demonstrated a positive correlation with CD4+ T cell preservation in the SIV-infected colons, indicating the profound effects of APOBEC3G. This was in contrast to pre-challenge polyfunctional CD8+ T cell responses, which were inversely correlated with postchallenge plasma viral loads, but surprisingly did not correlate with post-infection CD4+ T cell preservation in the colon at all. We further explored cytokine/chemokine expression levels, gp120 binding and neutralizing antibodies, and post-challenge mucosal viral-specific tetramer+ CD8+ T cell responses, and found that a significantly higher level of SIV-specific tetramer responses in the colons of the adjuvanted animals was induced/maintained even 6 months after SIVmac251 challenge compared to those without adjuvant. These SIV-specific tetramer responses were also positively correlated with the CD4+ T cell preservation. It is unusual here to see tetramer responses after 6 months of infection correlating with vaccine efficacy, as such responses are heavily influenced by viral load, which did not correlate.

Taken together, we found that the usage of certain molecular adjuvants in HIV mucosal vaccines was beneficial for improving the gut CD4+ memory T cell numbers upon infection, unexpectedly independent of its effect on VL, and thus might be useful for future HIV vaccine design.

Section snippets

Rhesus macaques, immunization and challenge

25 Indian rhesus macaques (Macaca mulatta) were immunized and challenged as previously described [25]. Briefly, the macaques were maintained in accordance with guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care International and with approval of the NCI Animal Care and Use Committee. They were all seronegative for SIV, simian retroviruses 1, 2 and 5, and simian T-cell leukemia/lymphotropic virus type 1 prior to the study. All macaques were Mamu-A*01+,

CD4+ memory T cell numbers were preserved after SIV infection in the colons of the macaques immunized with vaccines containing adjuvants

In our recent macaque study, we have intrarectally immunized four groups of macaques with a peptide-prime, MVA-boost SIV vaccine regimen with or without adjuvant: group 1 adjuvanted with a combination of TLR 2, 3, and 9 agonists, group 2 with IL-15, group 3 with both TLR agonists and IL-15, and group 4 with vaccine but without any adjuvant [25]. A group 5 was added with TLR agonists and IL-15 adjuvant only but without vaccine as an adjuvant control group [25]. Upon SIVmac251 challenge, only

Discussion

In our recent SIV-macaque study, we have evaluated the protective efficacy of using TLR agonists, IL-15 and the combination of these two as adjuvants in a peptide-primed/MVA-boosted mucosal SIV vaccine against intrarectal SIVmac251 challenge [25]. As shown before, mucosal administration of the combination of both adjuvants in the macaques induced high levels of antigen-specific CD4+ and polyfunctional CD8+ T cell responses after immunization, and conferred partial protection against the

Acknowledgments

This work was supported in part by the Intramural Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research, and the NIH Intramural AIDS Targeted Antiretroviral Program. We thank the NIAID tetramer core facility for providing the tetramers.

References (66)

  • S. Mehandru et al.

    Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection

    PLoS Med

    (2006)
  • S. Sankaran et al.

    Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors

    Proc Natl Acad Sci USA

    (2005)
  • B. Ling et al.

    Early restoration of mucosal CD4 memory CCR5 T cells in the gut of SIV-infected rhesus predicts long term non-progression

    AIDS

    (2007)
  • N.L. Letvin et al.

    Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

    Science

    (2006)
  • M. Vaccari et al.

    Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency

    J Virol

    (2008)
  • U. Wille-Reece et al.

    Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

    J Exp Med

    (2006)
  • M. Kwissa et al.

    Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus

    J Exp Med

    (2007)
  • A. Iwasaki et al.

    Toll-like receptor control of the adaptive immune responses

    Nat Immunol

    (2004)
  • Q. Zhu et al.

    Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines

    PNAS

    (2008)
  • Q. Zhu et al.

    Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice

    J Clin Invest

    (2010)
  • T.C. Becker et al.

    Interleukin 15 is required for proliferative renewal of virus-specific memory CD8T cells

    J Exp Med

    (2002)
  • E.J. Wherry et al.

    Homeostatic proliferation but not the generation of virus specific memory CD8T cells is impaired in the absence of IL-15 or IL-15Ralpha

    Adv Exp Med Biol

    (2002)
  • J.T. Tan et al.

    Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells

    J Exp Med

    (2002)
  • A.D. Judge et al.

    Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells

    J Exp Med

    (2002)
  • S. Oh et al.

    IL-15/IL-15R alpha-mediated avidity maturation of memory CD8+ T cells

    Proc Natl Acad Sci USA

    (2004)
  • S. Oh et al.

    IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis

    Proc Natl Acad Sci USA

    (2008)
  • J.D. Boyer et al.

    Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid

    Proc Natl Acad Sci USA

    (2007)
  • M.A. Kutzler et al.

    Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8T cells that are partially independent of CD4T cell help

    J Immunol

    (2005)
  • Y. Sui et al.

    Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques

    Proc Natl Acad Sci USA

    (2010)
  • J.L. Dzuris et al.

    Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules

    J Virol

    (2001)
  • I.M. Belyakov et al.

    Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

    Nat Med

    (2001)
  • L.J. Patterson et al.

    Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

    J Virol

    (2004)
  • V. Cecchinato et al.

    Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection

    J Immunol

    (2008)
  • Cited by (0)

    1

    Present address: University of Michigan, School of Medicine, Ann Arbor, MI, United States.

    View full text